Nanning Duoling Biotechnology

Nanning Duoling Biotechnology is a clinical-stage biopharmaceutical company based in Nanning, China, specializing in the development of recombinant protein vaccines for bacterial infections. The company focuses on addressing significant unmet medical needs, particularly pathogens for which no effective vaccines currently exist, such as Group A Streptococcus and Pseudomonas aeruginosa. Duoling Biotechnology utilizes a proprietary technology platform for high-efficiency protein expression and purification to create stable and immunogenic vaccine candidates. Its lead program, a recombinant Group A Streptococcus vaccine, is currently undergoing clinical evaluation in China. The company's broader pipeline includes candidates targeting Staphylococcus aureus and other hospital-acquired infections. By leveraging its integrated R&D and manufacturing capabilities, Duoling Biotechnology aims to provide innovative solutions to combat global antibiotic resistance.